Investment Management Corp of Ontario Has $10.55 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Investment Management Corp of Ontario increased its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 157.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,904 shares of the biotechnology company's stock after purchasing an additional 18,278 shares during the quarter. Investment Management Corp of Ontario owned approximately 0.07% of United Therapeutics worth $10,551,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC raised its holdings in United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock worth $1,761,000 after purchasing an additional 39 shares during the period. Wedmont Private Capital bought a new stake in shares of United Therapeutics in the fourth quarter valued at about $466,000. Signet Financial Management LLC lifted its stake in United Therapeutics by 1.0% in the 4th quarter. Signet Financial Management LLC now owns 10,816 shares of the biotechnology company's stock valued at $3,816,000 after acquiring an additional 103 shares in the last quarter. Park Avenue Securities LLC boosted its holdings in United Therapeutics by 18.4% during the fourth quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company's stock worth $922,000 after purchasing an additional 407 shares during the last quarter. Finally, Burney Co. boosted its stake in shares of United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after buying an additional 12,705 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

Shares of UTHR stock opened at $301.42 on Friday. United Therapeutics Co. has a one year low of $263.56 and a one year high of $417.82. The business's 50 day simple moving average is $300.53 and its 200 day simple moving average is $342.07. The stock has a market capitalization of $13.60 billion, a PE ratio of 13.24, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company posted $6.17 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 75,500 shares of company stock valued at $24,245,880 in the last ninety days. 11.90% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Finally, StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.